Sirolimus for Retinal Astrocytic Hamartoma

NACompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

March 22, 2024

Study Completion Date

March 22, 2024

Conditions
Retinal Astrocytic Hamartoma
Interventions
DRUG

Sirolimus

"An intravitreal injection of 20 µL of drug will be given through the pars plana of the eye. The injected eye will be treated with topical antibiotic and steroid eye drops prescribed for 7 to 10 days after the injection. The first injection will only be provided into the worse eye despite both eyes showing signs of exudation. Injection into the other eye will be considered only two months after the safety of this first injection is determined.~Safety and efficacy of treatment will be determined by repeat eye examinations in the eye clinic one day, one week and one month after each injection.~The interval between injections is roughly suggested to be between 3 to 8 weeks based on the drug deposit present in the eye. A total of 3-12 injections will be given per eye, over 6-24 months."

Trial Locations (1)

M5G1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER

NCT04707209 - Sirolimus for Retinal Astrocytic Hamartoma | Biotech Hunter | Biotech Hunter